Sugi Predict

Sugi Predict / Compounds / SCHEMBL584549

SCHEMBL584549

SCHEMBL584549

CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1CO

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.49
▸ CYP1A2 P05177 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ CHRM2 P08172 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ CHRM3 P20309 1/20 0.45
▸ SRC P12931 8/20 0.41
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2683392 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL11099691 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL1368985 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL5155598 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL12235723 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL15909556 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL12824048 1.00 NR1H2 (0.49) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL6421616 0.90 NR1H2 (0.48) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL1722772 0.87 CYP1A2 (0.45) NR1H2CYP1A2POLBCYP3A4CYP2C19
SCHEMBL20371652 0.87 CYP1A2 (0.45) NR1H2CYP1A2POLBCYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125386-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS THERAS INC (US) 2026-05-07 — — US disclosed
EP-4735438-A2 HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS Merck Patent GmbH (DE) 2026-05-06 — — EP disclosed
US-20260116891-A1 Oxazepin Derivative TEIJIN PHARMA LTD (JP) 2026-04-30 — — US disclosed
EP-4709729-A1 PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER Jazz Pharmaceuticals Ireland Ltd. (IE) 2026-03-18 — — EP disclosed
US-12552783-B2 Modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-17 — — US disclosed
EP-4612156-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-4577520-A1 PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF Renagade Therapeutics Management Inc. (US) 2025-07-02 — — EP disclosed
EP-4565579-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS Theras, Inc. (US) 2025-06-11 — — EP disclosed
EP-4512811-A1 OXAZEPINE DERIVATIVE Teijin Pharma Limited (JP) 2025-02-26 — — EP disclosed
US-20250034200-A1 Prodrugs of Neurosteroid Analogs and Uses Thereof UNIV EMORY (US) 2025-01-30 — — US disclosed
US-20040024059-A1 Novel pleuromutilin derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-05 — — US disclosed
US-20030216374-A1 Antibiotic oxazolidinone derivatives SYNGENTA LIMITED (GB) 2003-11-20 — — US disclosed
EP-1351959-A1 NOVEL PLEUROMUTILIN DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 2003-10-15 — — EP disclosed
US-6605630-B1 Active against drug resistant gram positive pathogens SYNGENTA LIMITED (GB) 2003-08-12 — — US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 — — US disclosed
WO-2002072087-A1 PCRA HELICASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-09-19 — — WO disclosed
WO-2002030929-A1 NOVEL PLEUROMUTILIN DERIVATIVES SMITHKLINE BEECHAM P.L.C. (GB) 2002-04-18 — — WO disclosed
EP-1005468-A1 ANTIBIOTIC OXAZOLIDINONE DERIVATIVES ZENECA LIMITED (GB) 2000-06-07 — — EP disclosed
WO-2000023444-A1 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2000-04-27 — — WO disclosed
WO-1999010342-A1 ANTIBIOTIC OXAZOLIDINONE DERIVATIVES ZENECA LIMITED (GB) 1999-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 NR1H2 2538/4885CYP1A2 2573/4885POLB 4473/4885
US-20040024059-A1 Novel pleuromutilin derivatives PLEC, MLNR, FABP2 NR1H2 3640/4885CYP1A2 3641/4885POLB 1433/4885
US-20260125386-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS KRAS, NRAS, HRAS NR1H2 1693/4885CYP1A2 3305/4885POLB 1779/4885
US-20250034200-A1 Prodrugs of Neurosteroid Analogs and Uses Thereof CYP11B2, CYP11B1, CYP21A2 NR1H2 57/4885CYP1A2 81/4885POLB 3554/4885
US-12552783-B2 Modulators of proteolysis and associated methods of use CRBN, ADRM1, MDM2 NR1H2 2761/4885CYP1A2 4695/4885POLB 3240/4885
US-20030216374-A1 Antibiotic oxazolidinone derivatives OXA1L, HRH1, OGDH NR1H2 43/4885CYP1A2 132/4885POLB 1180/4885
US-20260116891-A1 Oxazepin Derivative HCRTR2, HCRTR1, OXTR NR1H2 71/4885CYP1A2 899/4885POLB 4790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.